 | Up a level |
Chaplin, Marty 
ORCID: 0000-0002-7097-8704, Bresnahan, Rebecca, Fleeman, Nigel ORCID: 0000-0002-4637-9779, Mahon, James, Houten, Rachel ORCID: 0000-0002-4315-7732, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela ORCID: 0000-0002-5435-8644, Dundar, Yenal, Marsden, Ashley and Munot, Pinki
(2023)
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.
PharmacoEconomics - Open, 7 (6).
pp. 863-875.
Houten, Rachel ORCID: 0000-0002-4315-7732, Fleeman, Nigel ORCID: 0000-0002-4637-9779, Mahon, James, Chaplin, Marty, Edwards, Katherine, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela ORCID: 0000-0002-5435-8644, Dundar, Yenal, Marsden, Ashley, Malik, Zafar et al (show 1 more authors)
(2023)
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
PHARMACOECONOMICS-OPEN, 7 (3).
pp. 345-358.